Adverse Drug Experience Communications and Reporting Industry Perspective: Regulations and Practice

Abstract

Adverse drug experience (ADE) reporting and communications are a critical responsibility of the pharmaceutical industry. This process can directly affect health care, but it has important regulatory implications. This paper briefly describes the regulatory responsibilities of the industry, how the regulations impact the type of information available from company databases, and how pharmaceutical companies communicate with health professionals about adverse drug events.